Step Capital Management Pte. Ltd. Acquires New Position in Tempus AI, Inc. $TEM

Step Capital Management Pte. Ltd. acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the fourth quarter, HoldingsChannel reports. The fund acquired 20,000 shares of the company’s stock, valued at approximately $1,181,000. Tempus AI comprises about 0.5% of Step Capital Management Pte. Ltd.’s investment portfolio, making the stock its 16th largest holding.

A number of other institutional investors have also recently bought and sold shares of TEM. Sowell Financial Services LLC lifted its stake in shares of Tempus AI by 11.6% in the 4th quarter. Sowell Financial Services LLC now owns 3,640 shares of the company’s stock valued at $215,000 after purchasing an additional 378 shares during the period. Sugar Maple Asset Management LLC boosted its position in shares of Tempus AI by 120.0% in the 4th quarter. Sugar Maple Asset Management LLC now owns 11,000 shares of the company’s stock worth $650,000 after purchasing an additional 6,000 shares during the last quarter. Aberdeen Group plc grew its stake in shares of Tempus AI by 64.2% during the fourth quarter. Aberdeen Group plc now owns 263,004 shares of the company’s stock worth $15,530,000 after purchasing an additional 102,878 shares during the period. Victory Financial Group LLC bought a new stake in Tempus AI in the fourth quarter valued at about $754,000. Finally, Lodestone Wealth Management LLC bought a new stake in Tempus AI in the fourth quarter valued at about $42,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

Tempus AI Price Performance

Shares of TEM opened at $47.39 on Monday. The company has a current ratio of 3.13, a quick ratio of 3.00 and a debt-to-equity ratio of 2.52. The company’s fifty day simple moving average is $52.98 and its 200 day simple moving average is $68.15. Tempus AI, Inc. has a 1-year low of $36.22 and a 1-year high of $104.32. The company has a market cap of $8.47 billion, a price-to-earnings ratio of -33.61 and a beta of 4.90.

Insider Activity at Tempus AI

In other news, CFO James William Rogers sold 10,084 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $595,460.20. Following the sale, the chief financial officer directly owned 101,166 shares of the company’s stock, valued at approximately $5,973,852.30. This represents a 9.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Erik Phelps sold 9,464 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.43, for a total transaction of $562,445.52. Following the completion of the sale, the executive vice president owned 79,816 shares of the company’s stock, valued at $4,743,464.88. This trade represents a 10.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 563,841 shares of company stock worth $32,258,311 over the last ninety days. Company insiders own 26.27% of the company’s stock.

Analysts Set New Price Targets

TEM has been the topic of several analyst reports. Canaccord Genuity Group reduced their target price on Tempus AI from $95.00 to $80.00 and set a “buy” rating on the stock in a report on Monday, December 22nd. Wall Street Zen cut Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. BTIG Research cut their price target on shares of Tempus AI from $105.00 to $90.00 and set a “buy” rating on the stock in a research report on Wednesday, February 25th. Morgan Stanley reduced their price objective on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Finally, HC Wainwright boosted their price objective on shares of Tempus AI from $89.00 to $95.00 and gave the company a “buy” rating in a report on Monday, March 9th. Eight investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $75.92.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.